{"id":824107,"date":"2025-03-11T07:34:26","date_gmt":"2025-03-11T11:34:26","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-to-participate-in-the-37th-annual-roth-conference\/"},"modified":"2025-03-11T07:34:26","modified_gmt":"2025-03-11T11:34:26","slug":"promis-neurosciences-to-participate-in-the-37th-annual-roth-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-to-participate-in-the-37th-annual-roth-conference\/","title":{"rendered":"ProMIS Neurosciences to Participate in the 37th Annual Roth Conference"},"content":{"rendered":"
\n

CAMBRIDGE, Massachusetts, March 11, 2025 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer\u2019s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will participate in a fireside chat at the 37th<\/sup> Annual Roth Conference on Tuesday, March 18, 2025 at 8:00 a.m. PT in Dana Point, CA.<\/p>\n

\n

A live webcast of the fireside chat may be accessed by visiting the Events page of the Company\u2019s website at www.promisneurosciences.com<\/u><\/a>, and will be available for at least 30 days following the event.<\/p>\n

\n About ProMIS Neurosciences Inc.<\/b>\n <\/p>\n<\/p>\n

ProMIS Neurosciences Inc. is a clinical stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer\u2019s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company\u2019s proprietary target discovery engine applies a thermodynamic, computational discovery platform – ProMIS\u2122 and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. PMN310, the Company\u2019s lead product candidate for the treatment of AD, is a differentiated, humanized monoclonal antibody that has been designed to specifically bind toxic A\u03b2 oligomers and to not bind plaque or monomers. Oligomers are known to drive disease progression in AD and PMN310 appears to selectively bind oligomers. PMN 310 has successfully completed a Phase 1a clinical study and is dosing Alzheimer\u2019s disease patients in a Phase 1b clinical trial in AD patients. ProMIS has offices in Cambridge, Massachusetts and Toronto, Ontario.<\/p>\n<\/p>\n

\n For further information:<\/b>\n <\/p>\n<\/p>\n

Visit us at www.promisneurosciences.com<\/u><\/a>.<\/p>\n<\/p>\n

Please submit media inquiries to info@promisneurosciences.com<\/u><\/a>.<\/p>\n<\/p>\n

\n For Investor Relations, please contact: <\/b>\n <\/p>\n

Precision AQ (formerly Stern IR)
Anne Marie Fields, Managing Director
annemarie.fields@precisionaq.com
Tel. 212-362-1200<\/p>\n

\n

\u00a0<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

\n
<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"
CAMBRIDGE, Massachusetts, March 11, 2025 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer\u2019s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will participate in a fireside chat at the 37th Annual Roth Conference on Tuesday, March 18, 2025 at 8:00 a.m. PT in Dana Point, CA. A live webcast of the fireside chat may be accessed by visiting the Events page of the Company\u2019s website at www.promisneurosciences.com, and will be available for at least 30 days following the event. About ProMIS Neurosciences Inc. … <\/p>\n
Continue reading “ProMIS Neurosciences to Participate in the 37th Annual Roth Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-824107","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nProMIS Neurosciences to Participate in the 37th Annual Roth Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-to-participate-in-the-37th-annual-roth-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ProMIS Neurosciences to Participate in the 37th Annual Roth Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Massachusetts, March 11, 2025 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer\u2019s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will participate in a fireside chat at the 37th Annual Roth Conference on Tuesday, March 18, 2025 at 8:00 a.m. PT in Dana Point, CA. A live webcast of the fireside chat may be accessed by visiting the Events page of the Company\u2019s website at www.promisneurosciences.com, and will be available for at least 30 days following the event. About ProMIS Neurosciences Inc. … Continue reading "ProMIS Neurosciences to Participate in the 37th Annual Roth Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-to-participate-in-the-37th-annual-roth-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-11T11:34:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5MjM0NSM2ODAwMjQyIzIwODQ1ODk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/promis-neurosciences-to-participate-in-the-37th-annual-roth-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/promis-neurosciences-to-participate-in-the-37th-annual-roth-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ProMIS Neurosciences to Participate in the 37th Annual Roth Conference\",\"datePublished\":\"2025-03-11T11:34:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/promis-neurosciences-to-participate-in-the-37th-annual-roth-conference\\\/\"},\"wordCount\":325,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/promis-neurosciences-to-participate-in-the-37th-annual-roth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5MjM0NSM2ODAwMjQyIzIwODQ1ODk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/promis-neurosciences-to-participate-in-the-37th-annual-roth-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/promis-neurosciences-to-participate-in-the-37th-annual-roth-conference\\\/\",\"name\":\"ProMIS Neurosciences to Participate in the 37th Annual Roth Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/promis-neurosciences-to-participate-in-the-37th-annual-roth-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/promis-neurosciences-to-participate-in-the-37th-annual-roth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5MjM0NSM2ODAwMjQyIzIwODQ1ODk=\",\"datePublished\":\"2025-03-11T11:34:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/promis-neurosciences-to-participate-in-the-37th-annual-roth-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/promis-neurosciences-to-participate-in-the-37th-annual-roth-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/promis-neurosciences-to-participate-in-the-37th-annual-roth-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5MjM0NSM2ODAwMjQyIzIwODQ1ODk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5MjM0NSM2ODAwMjQyIzIwODQ1ODk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/promis-neurosciences-to-participate-in-the-37th-annual-roth-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ProMIS Neurosciences to Participate in the 37th Annual Roth Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ProMIS Neurosciences to Participate in the 37th Annual Roth Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-to-participate-in-the-37th-annual-roth-conference\/","og_locale":"en_US","og_type":"article","og_title":"ProMIS Neurosciences to Participate in the 37th Annual Roth Conference - Market Newsdesk","og_description":"CAMBRIDGE, Massachusetts, March 11, 2025 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer\u2019s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will participate in a fireside chat at the 37th Annual Roth Conference on Tuesday, March 18, 2025 at 8:00 a.m. PT in Dana Point, CA. A live webcast of the fireside chat may be accessed by visiting the Events page of the Company\u2019s website at www.promisneurosciences.com, and will be available for at least 30 days following the event. About ProMIS Neurosciences Inc. … Continue reading \"ProMIS Neurosciences to Participate in the 37th Annual Roth Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-to-participate-in-the-37th-annual-roth-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-11T11:34:26+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5MjM0NSM2ODAwMjQyIzIwODQ1ODk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-to-participate-in-the-37th-annual-roth-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-to-participate-in-the-37th-annual-roth-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ProMIS Neurosciences to Participate in the 37th Annual Roth Conference","datePublished":"2025-03-11T11:34:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-to-participate-in-the-37th-annual-roth-conference\/"},"wordCount":325,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-to-participate-in-the-37th-annual-roth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5MjM0NSM2ODAwMjQyIzIwODQ1ODk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-to-participate-in-the-37th-annual-roth-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-to-participate-in-the-37th-annual-roth-conference\/","name":"ProMIS Neurosciences to Participate in the 37th Annual Roth Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-to-participate-in-the-37th-annual-roth-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-to-participate-in-the-37th-annual-roth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5MjM0NSM2ODAwMjQyIzIwODQ1ODk=","datePublished":"2025-03-11T11:34:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-to-participate-in-the-37th-annual-roth-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-to-participate-in-the-37th-annual-roth-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-to-participate-in-the-37th-annual-roth-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5MjM0NSM2ODAwMjQyIzIwODQ1ODk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5MjM0NSM2ODAwMjQyIzIwODQ1ODk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/promis-neurosciences-to-participate-in-the-37th-annual-roth-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ProMIS Neurosciences to Participate in the 37th Annual Roth Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/824107","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=824107"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/824107\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=824107"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=824107"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=824107"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}